HepaStem Long-Term Safety Registry

Primary outcomes

• Occurrence of Adverse Events of Specific Interest (AESI) [60 months]: Adverse Events of Specific Interest (AESI): * Event with fatal outcome (Death) * Orthotopic Liver Transplantation (OLT) and Outcome. * Development of Malignancy or unwanted tissue formation in different organs (tumor malignant or not). * Disease linked to transmission of adventitious agents or reactivation of latent pathogens. * Any AE which in the opinion of the Investigator has a plausible causal relationship to HepaStem.

Sex: All, ages: 5 Years to 75 Years

Inclusion Criteria:

* All patients having received at least one infusion of HepaStem during a previous interventional clinical study conducted by Promethera.

Exclusion Criteria:

* Patients who received an OLT and completed 6-month FU documentation prior to the start of the PROLONGSTEM study.
* Patients who have received mature liver cells or stem cells other than HepaStem prior to the start of the PROLONGSTEM study.